Share
.webp)
.webp)
.webp)
.webp)
Jeannie Lee
GSK plc has announced the appointment of Dr. Jeannie Lee to its Board as a Non-Executive Director.
Dr. Lee is currently the Phillip A. Sharp, PhD, Endowed Chair in Molecular Biology and Acting Chair of the Department of Molecular Biology at Massachusetts General Hospital. She also serves as a Professor of Genetics and Pathology at Harvard Medical School. A leading figure in RNA biology, Dr. Lee has made significant contributions to drug development and therapeutics in this field. In addition to her leadership roles at Harvard and Massachusetts General Hospital, Dr. Lee co-founded Translate Bio and Fulcrum Therapeutics, two biotechnology companies focused on RNA and epigenetic therapies.
Dr. Lee is a member of the National Academy of Sciences and the National Academy of Medicine. She has received numerous awards, including the Lurie Prize from the Foundation for the National Institutes of Health, the Centennial Prize from the Genetics Society of America, and both the Molecular Biology Prize and Cozzarelli Prize from the National Academy of Sciences. She is also a Fellow of the American Association for the Advancement of Science and has served on the Board of the Genetics Society of America.
Sir Jonathan Symonds, Chair of GSK, commented, "We are thrilled to welcome Jeannie to the GSK Board. Her profound expertise in scientific and medical innovation, particularly in RNA biology and epigenetics—key areas of focus for GSK’s R&D—along with her public health experience, will add tremendous value to our Board’s perspective."
